Table 1 Correlation between the expression of Nogo-B and the clinicopathologic features of NPC.
From: Nogo-B promotes invasion and metastasis of nasopharyngeal carcinoma via RhoA-SRF-MRTFA pathway
|  | All cases (n = 116) | Nogo-B expression | P-value | |
|---|---|---|---|---|
Low (n = 63) | High (n = 53) | |||
Age (years) | Â | Â | Â | 0.401 |
 <46 | 52 | 26 (41.3%) | 26 (49.1%) | |
 ≥46 | 64 | 37 (58.7%) | 27 (50.9%) | |
Gender | 0.747 | |||
 Female | 29 | 15 (23.8%) | 14 (26.4%) | |
 Male | 87 | 48 (76.2%) | 39 (73.6%) | |
T stage | 0.532 | |||
 T1-2 | 54 | 31 (49.2%) | 23 (43.4%) | |
 T3-4 | 62 | 32 (50.8%) | 30 (56.6%) | |
N stage | <0.001* | |||
 N0-1 | 47 | 38 (60.3%) | 9 (17.0%) | |
 N2-3 | 69 | 25 (39.7%) | 44 (83.0%) | |
M stage | 0.023a* | |||
 M0 | 108 | 62 (98.4%) | 46 (86.8%) | |
 M1 | 8 | 1 (1.6%) | 7 (13.2%) | |
TNM stage (UICC/AJCC 8th edition, 2017) | 0.001* | |||
 I–II | 38 | 29 (46.0%) | 9 (17.0%) | |
 III–IV | 78 | 34 (54.0%) | 44 (83.0%) | |
State | 0.006* | |||
 Survival | 99 | 59 (93.7%) | 40 (75.5%) | |
 Death | 17 | 4 (6.3%) | 13 (24.5%) | |
Recurrent | 0.003* | |||
 No | 98 | 59 (93.7%) | 39 (73.6%) | |
 Yes | 18 | 4 (6.3%) | 14 (26.4%) | |
Locoregional failure | 0.592a | |||
 No | 113 | 62 (98.4%) | 51 (96.2%) |  |
 Yes | 3 | 1 (1.6%) | 2 (3.8%) |  |
Distant metastasis failure | 0.002* | |||
 No | 100 | 60 (95.2%) | 40 (75.5%) |  |
 Yes | 16 | 3 (4.8%) | 13 (24.5%) |  |
